Unassociated Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  March 16, 2009

Brainstorm Cell Therapeutics Inc.
(Exact name of registrant as specified in its charter)

Delaware
    
333-61610
    
20-8133057
(State or other jurisdiction of incorporation)
    
(Commission File No.)
    
(IRS Employer Identification No.)
 
110 East 59th Street
  
New York, New York
10022
(Address of principal executive offices)
(Zip Code)

(212) 557-9000
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
 
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
  
(d) Election of Director

On March 16, 2009, the Board of Directors of BrainStorm Cell Therapeutics Inc. (the “Company”) elected Malcolm Taub to the Board of Directors.

There have been no transactions and are no currently proposed transactions to which the Company or any of its subsidiaries was or is a party in which Mr. Taub has a material interest, which are required to be disclosed under Item 404(a) of Regulation S-K.  Consistent with the compensation paid to the other members of the Board of Directors, on March 16, 2009, the Company issued a fully vested stock option to Mr. Taub for the purchase of 100,000 shares of its common stock at an exercise price of $0.10 and with an expiration date of ten years after the grant date.

 
 
 
 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
March 19, 2009 
Brainstorm Cell Therapeutics Inc.
  
       
 
By:
/s/ Chaim Lebovits 
  
   
Chaim Lebovits 
  
   
President